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Clinical Update
PULMONARY ARTERIAL HYPERTENSION (PAH) is gener-
ally considered a rare and rapidly lethal condition with poor
prognosis and few or no treatment options.1,2 However,
PAH is a generic term that includes elevated pulmonary
vascular resistance due to a wide range of causes (Box 1).3
PAH is defined as a mean pulmonary arterial pressure of
>25 mmHg at rest and >30 mmHg with exercise. Primary
pulmonary hypertension has an estimated incidence of 2 per
million population (possibly higher), with PAH associated
with other diseases showing a higher incidence.3 PAH is
often not detected until the late and highly symptomatic
stage. There is increasing recognition that PAH associated
with other diseases (eg, connective tissue diseases such as
scleroderma, airways diseases, interstitial lung disease and
sleep apnoea) contributes to exercise intolerance and is a
threat to survival. Perhaps in the past, with few treatment
options, late diagnosis of PAH was not critical. With new
drugs demonstrating efficacy in PAH, an active effort is
required to diagnose its presence early, when these treat-
ments may have greater effect.
Symptoms
Symptoms of mild-to-moderate PAH may be insidious. In
the early stages, breathlessness, palpitations, fatigue and a
pounding heart may be misinterpreted as lack of fitness or
cardiac ischaemia. As PAH progresses, ankle oedema and
later right-sided congestion (elevated jugular venous pres-
sure, ascites, hepatomegaly, peripheral oedema) occur. Syn-
cope is evident late in the disease. Unless the diagnosis is
considered and actively sought, it may be missed.4
Diagnosis
The most useful investigations are echocardiography and
respiratory function tests. The echocardiogram may show a
hypertrophied, dilated or hypokinetic right ventricle, tricus-
pid regurgitation and elevated pulmonary arterial pressure.
The left ventricle usually contracts normally, but may be
encroached upon by the enlarged right ventricle. In the
absence of a tricuspid regurgitation jet, pulmonary arterial
pressure cannot be determined on echocardiography and
the diagnosis is not excluded using this test. Respiratory
function tests show a disproportionate reduction in carbon
monoxide diffusion in the lung (DLCO) (around 50% of
predicted in moderate PAH), with at most a mild-to-
moderate restrictive lung defect. The reduction in DLCO is
greater than that seen with comparably symptomatic left
heart failure.
The definitive test for PAH is right heart catheterisation,
providing a direct measure of pulmonary pressures. Several
Australian centres perform this as an outpatient procedure,
via the right internal jugular vein under local anaesthetic.
Anticoagulation does not need to be ceased and fasting is
not required. Repetitive straight leg raising to increase
cardiac demand may uncover early cases in which PAH is
only present during exercise. The six-minute walk test is
informative and safe in assessing response to treatment and
has a strong independent association with mortality.5 Once
PAH has been detected, a comprehensive search for causes
should be undertaken (Box 2).
Screening
Patients with family history of primary PAH may have a
genetic predisposition to PAH, although the predictive value
of the BMPR2 gene, which has been associated with the
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disease, is not yet well defined.6 Up to 15% of patients with
scleroderma (especially limited scleroderma) ultimately
develop PAH, and annual screening with DLCO measure-
ment and echocardiography is advisable.
Treatment
PAH can be treated specifically (pulmonary thromboendar-
terectomy) or generically. Chronic thromboembolic pulmon-
ary hypertension is increasingly recognised as an important
cause of secondary PAH, for which pulmonary thrombo-
endarterectomy may provide definitive treatment.7 PAH
secondary to sleep apnoea may respond to continuous
positive airway pressure.8 PAH complicating connective tis-
sue disease is recognised as an independent predictor of
poorer prognosis in these conditions.9 Treatment here
should be along similar lines to that used in primary
pulmonary hypertension.
Until recently, access to effective drug treatment for severe
PAH has been very limited in Australia. Heart–lung trans-
plantation for primary pulmonary hypertension was first
performed at St Vincent’s Hospital, Sydney, in 1986. This
was the first putative “curative” therapy for this condition,
but is now appropriate only for patients with advanced
disease for whom medical therapy has failed. There is,
however, an increasing selection of vasodilator and remodel-
ling agents becoming available, providing promise of effect-
ive long term medical alternatives.10-14 British guidelines for
the diagnosis and treatment of PAH were recently published
and treatment algorithms are under development interna-
tionally.15
Medical therapies
The pathophysiological basis of PAH is an increase in
vasoconstrictor substances (thromboxane, endothelin) and a
reduction in vasodilatory substances (nitric oxide, prostacy-
clin) with smooth muscle cell proliferation and in situ
thrombosis, resulting in structural reduction in pulmonary
arterial lumen size and, ultimately, plexigenic arteriopathy.
Medical therapies for PAH (Box 3) consist of agents
which modify one or more of these pathogenetic mecha-
nisms:
■ anticoagulation (to prevent in situ thrombosis or throm-
boembolism; eg, warfarin, prostacyclin analogues);
■ vasodilators (eg, prostacyclin analogues, which increase
intracellular cyclic AMP, calcium antagonists, endothelin
antagonists, bosentan, and phosphodiesterase 5 inhibitors,
which increase cyclic GMP); and
■ long term antifibrotic and remodelling agents (prostacyc-
lin analogues and bosentan).
Atrial septostomy
For patients refractory to vasodilator therapy, atrial septo-
stomy may be considered. The aim of this intervention is to
relieve right-sided congestion and augment systemic cardiac
output. Experience with this procedure in Australia is
extremely limited, but its value has been suggested in a
number of small studies in other countries.24
Natural history
PAH is often a lethal condition or contributes to a poor
outlook, with the prognosis directly related to the severity of
the associated right ventricular dysfunction.2 Once right
ventricular failure ensues, the median survival for patients
without treatment is short. PAH, arising secondary to other
disorders, contributes to exercise intolerance and reduces
survival.
1: Common causes of pulmonary arterial 
hypertension*
1. Pulmonary arterial hypertension
Primary pulmonary arterial hypertension:
■ Sporadic
■ Familial (up to 25%)
Pulmonary arterial hypertension related to:
■ Connective tissue diseases (CREST syndrome, scleroderma, 
mixed connective tissue disease)
■ HIV
■ Congenital heart disease, Eisenmenger’s syndrome
■ Portopulmonary hypertension
■ Anorexigens
■ Primary pulmonary hypertension of the newborn
2. Pulmonary venous hypertension
■ Left heart diseases and left ventricular dysfunction
■ Pulmonary veno-occlusive disease
3. Disorders of the respiratory system
■ Chronic obstructive pulmonary disease
■ Interstitial lung diseases
■ Sleep disordered breathing
4. Chronic thromboembolic pulmonary hypertension
5. Disorders directly affecting pulmonary vasculature
* Adapted from the WHO Classification of pulmonary arterial hypertension.
2: Investigations in pulmonary arterial hypertension
■ Echocardiogram
■ Respiratory function tests: lung volumes, CO diffusion capacity
■ Chest x-ray
■ Ventilation perfusion scan
■ High resolution computed tomography (CT) scan of lungs
■ CT pulmonary angiogram
■ Connective tissue disease screen (antinuclear antibodies, anti-
dsDNA antibodies, anti-neutrophil cytoplasmic antibodies  
antitopoisomerase [SCL-70]  antifibrillarin [anti-RNP])
■ Thrombophilia screen (anticardiolipin antibody, lupus inhibitor, 
protein C, protein S, factor V Leiden, methyl tetrahydrofolate 
reductase mutation)
■ Sleep study
➤  contrast CT pulmonary angiogram
➤  coronary angiogram (consider >40 years old)
■ Right heart catheterisation for definitive diagnosis. (In PAH, mean 
pulmonary arterial pressure will be >25 mmHg at rest and 
>30 mmHg with exercise)
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Referral
With the increasing availability of effective treatment for
severe pulmonary hypertension, it is important that patients
are referred to centres offering the range of diagnostic and
therapeutic interventions. Assessing dose response, moni-
toring clinical outcomes, switching agents and applying
combination therapy (including different modalities)
requires considerable experience to ensure optimal out-
comes. Complex decisions are required in delineating
patients with chronic thromboembolic pulmonary hyperten-
sion suitable for pulmonary thromboendarterectomy and
the timing of listing for lung transplantation. These issues
have been recently addressed in the United Kingdom where
the National Health Service has designated national centres
for the assessment and management of severe pulmonary
hypertension.15 In addition, one centre only has been
nominated to perform pulmonary thromboendarterectomy
surgery, so as to ensure concentration of experience and
expertise.
Conclusion
Historically, Australia has been unable to offer patients with
PAH adequate treatment, largely because of the high cost of
therapy. The performance of pulmonary thromboendarter-
ectomy in Australia was recently shown to achieve success
rates similar to international practice. Transplantation con-
tinues to be limited by donor availability.
Now, with the availability of new and effective oral agents,
we can abandon the therapeutic nihilism of past decades,
and offer patients effective therapies. Some of these agents
allow reverse remodelling of the right ventricle within very
short periods. Reverse remodelling of the pulmonary artery
and the potential to reverse the entire disease process are
realistic targets.
This new era of effective agents gives clinicians a sound
reason to diagnose PAH, to tease out all contributing
elements and to detect cases early. Trials to date have been
performed in moderately to severely affected patients, but
are now in progress in less ill patients. As with most
cardiovascular diseases, earlier detection and intervention is
likely to be rewarded with better outcomes.
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